Study #2018-0192
A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb®13676 (Plamotamab) in Patients with CD20-Expressing Hematologic Malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
XmAb13676
Description
The purpose of this study is to determine the safety and tolerability of intravenous (IV) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
Information and next steps
Disease:
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Study phase:
I
Physician name:
Sairah Ahmed
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.